Sinovac Biotech, Ltd.
Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
Follow SVA
Sinovac Biotech, Ltd. (SVA) EV/Sales
As of 14 October 2026, Sinovac Biotech, Ltd. (SVA) trades at a EV/Sales of −0.5×. Over the past ten years it has ranged from −1.0× (June 2024) to 6.1× (August 2016); the current reading is higher than 44% of that period. That is below the Other industry median of 2.1× and below the Other sector median of 2.1×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −0.9× | — |
| FY2024 | −1.0× | — |
| FY2023 | −1.0× | — |
| FY2022 | −0.5× | — |
| FY2021 | −0.6× | — |
| FY2020 | −1.0× | — |
| FY2019 | 1.7× | 35.43% |
| FY2018 | 1.2× | (23.49%) |
| FY2017 | 1.6× | (62.12%) |
| FY2016 | 4.3× | 2.60% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2023 | −1.0× | — |
| Dec 2022 | −0.5× | — |
| Jun 2022 | −0.5× | — |
| Dec 2021 | −0.6× | — |
| 23 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| SVA Sinovac Biotech, Ltd. | −0.5× |
| JONE Jones Energy, Inc. compare | 4.1× |
| Other industry median | 2.1× |
| Other sector median | 2.1× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)